Evidence map›Paper›PMID 32641520›Full record

ArticleNeurology2020

Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment.

Aaron R Switzer, Ikreet Cheema, Cheryl R McCreary, Angela Zwiers, Anna Charlton, Ana Alvarez-Veronesi, Ramnik Sekhon, Charlotte Zerna, Randall B Stafford, Richard Frayne and 2 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05396287 (The Impact of Cerebral Anatomical Variations on Cerebrovascular Reactivity), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05396287 active not recruitingnot on this mapstarted 2022, after this paper: background citation

The Impact of Cerebral Anatomical Variations on Cerebrovascular Reactivity

TypeobservationalSponsorUniversity of Wisconsin, MadisonRan2022 to 2027Enrolled80ConditionsBrain Blood Flow, HealthyArmsMRI
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Cerebral amyloid angiopathy and the immune system.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  14. Article
  15. Neurovascular coupling in early stage dementia - A case-control study.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  16. PSEN2 and ABCA7 variants causing early-onset preclinical pathological changes in Alzheimer's disease: a case report and literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Aaron R SwitzerFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Ikreet CheemaFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Cheryl R McCrearyFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Angela ZwiersFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Anna CharltonFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Ana Alvarez-VeronesiFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Ramnik SekhonFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Charlotte ZernaFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Randall B StaffordFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Richard FrayneFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.ORCID 0000-0003-0358-1210
Bradley G GoodyearFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada.
Eric E SmithFrom the Department of Clinical Neurosciences (A.R.S., C.R.M., A.Z., A.C., A.A.-V., R.S., C.Z., R.B.S., R.F., B.G.G., E.E.S), Hotchkiss Brain Institute (R.F., B.G.G., E.E.S), Department of Community Health Sciences (C.Z., E.E.S), and Department of Radiology (R.F., B.G.G., E.E.S), University of Calgary, Alberta; Faculty of Medicine (I.C.), University of Toronto, Ontario; and Seaman Family MR Research Centre (C.R.M., R.F., B.G.G.), Foothills Medical Centre, Calgary, Alberta, Canada eesmith@ucalgary.ca.
University of Calgary · CA

Funding

CIHR
6 · The paper itself

Abstract

objectiveTo assess cerebrovascular reactivity in response to a visual task in participants with cerebral amyloid angiopathy (CAA), Alzheimer disease (AD), and mild cognitive impairment (MCI) using fMRI.

methodsThis prospective cohort study included 40 patients with CAA, 22 with AD, 27 with MCI, and 25 healthy controls. Each participant underwent a visual fMRI task using a contrast-reversing checkerboard stimulus. Visual evoked potentials (VEPs) were used to compare visual cortex neuronal activity in 83 participants. General linear models using least-squares means, adjusted for multiple comparisons with the Tukey test, were used to estimate mean blood oxygen level-dependent (BOLD) signal change during the task and VEP differences between groups.

resultsAfter adjustment for age and hypertension, estimated mean BOLD response amplitude was as follows: CAA 1.88% (95% confidence interval [CI] 1.60%-2.15%), AD 2.26% (1.91%-2.61%), MCI 2.15% (1.84%-2.46%), and control 2.65% (2.29%-3.00%). Only patients with CAA differed from controls (

conclusionsMean visual BOLD response amplitude was lowest in participants with CAA compared to controls, without differences in VEP latencies and amplitudes. This suggests that the impaired visual BOLD response is due to reduced vascular reactivity in CAA. In contrast to participants with CAA, the visual BOLD response amplitude did not differ between those with AD or MCI and controls.

Indexed as

AgedAlzheimer DiseaseCerebral Amyloid AngiopathyCerebrovascular CirculationCognitive DysfunctionCohort StudiesCross-Sectional StudiesEcho-Planar ImagingEvoked Potentials, VisualFemaleHumansImage Interpretation, Computer-AssistedMaleMiddle AgedProspective StudiesVisual Cortex

Identifiers

PMID32641520
PMCPMC7538216
OpenAlexW3040775080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.